Stadtroda

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Researchers are evaluating the efficacy and safety of NIO752 in adults aged 41 to 81 with Progressive Supranuclear Palsy Richardson Syndrome PSP-RS, a rare neurological disorder. This Phase III randomized, double-blind, placebo-controlled study compares NIO752 to a placebo in participants with mild to moderate PSP, with symptoms starting less than five years ago. The study is sponsored by Novartis Pharmaceuticals and includes an open-label extension after the initial treatment period. Participants will be randomly assigned in a 21 ratio to receive either NIO752 solution or a placebo solution. After completing the double-blind treatment phase, all participants will have the option to continue receiving NIO752 in an open-label extension. The study monitors changes over 72 weeks, with various assessments including brain imaging and biomarker analysis. During the study, participants and their reliable study partners will attend regular visits for evaluations such as cognitive testing, daily living activities, and safety monitoring. Researchers will measure changes from baseline in PSP rating scales and other neurological functions. Safety will be assessed by tracking adverse events, and the total participation may last up to several years including the open-label extension.

Parkinsons disease is a neurological condition that affects the brain and worsens over time, with symptoms like tremors, stiffness, and slow movement. Researchers are evaluating how effective foscarbidopafoslevodopa is in treating adult German participants who are in the early stages of advanced Parkinsons disease under routine clinical care. This observational study includes about 125 adults prescribed this treatment by their doctors in Germany. Participants will receive foscarbidopafoslevodopa via subcutaneous infusion as their physician prescribes, following local label instructions. The treatment is given during usual clinical visits without extra interventions specifically for the study. Participants will be followed for up to 12 months to monitor their treatment experience and outcomes. During the study, participants will attend regular hospital or clinic visits as part of their routine care. Researchers will assess changes in OFF time, which refers to periods when Parkinsons symptoms return or worsen, measuring this for up to 12 months. There is no expected additional burden beyond standard care, and participant safety and quality of life will be monitored throughout the study period.

This research aims to systematically record the results of routine laryngeal examinations and specific swallowing difficulties in patients with various neurodegenerative diseases such as Multiple System Atrophy MSA, Progressive Supranuclear Palsy PSP, Parkinsons Disease, Motor Neuron Disease MND, and other related conditions. These disorders often lead to swallowing problems known as dysphagia, which can cause serious complications like dehydration, malnutrition, and pneumonia. The study seeks to better understand how these swallowing issues vary with different disease types and stages. Participants undergo a fiberoptic or flexible endoscopic evaluation of swallowing FEES using a structured task protocol designed to assess laryngopharyngeal function. When available, laryngeal electromyography EMG results are also collected. The study includes patients diagnosed according to established diagnostic criteria for their specific neurodegenerative disorder. Data collected also include demographic information and disease-specific details, along with responses to two questionnaires assessing swallowing disturbances and quality of life related to swallowing. During the study, participants will have their swallowing function assessed through FEES and complete questionnaires about their swallowing difficulties and quality of life. Researchers will evaluate laryngeal movement disorders and dysphagia as primary outcomes. This observational study does not involve any treatment intervention and aims to follow participants over time to categorize swallowing issues and correlate them with their disease subtype. The study has been ongoing since 2017 and plans to continue recruitment and data collection through 2028.